Fig. 1: Kaplan–Meier estimates of overall survival.
From: Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer
a, b, Overall survival with nivolumab plus chemotherapy versus chemotherapy in patients with PD-L1 CPS ≥ 5 (a) and in all randomized patients (b). Minimum follow-up, 24.0 months. c, d, Overall survival with nivolumab plus ipilimumab versus chemotherapy in patients with PD-L1 CPS ≥ 5 (c) and in all randomized patients (d). Minimum follow-up, 35.7 months. Chemo, chemotherapy; CI, confidence interval; HR, hazard ratio; IPI, ipilimumab; NIVO, nivolumab; OS, overall survival.
